Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx®) in Germany between 2001 and 2004;Schätzung der unter rofecoxib (Vioxx®) in Deutschland in den jahren 2001-2004 aufgetretenen kardio- und zerebrovaskulären ereignisse

Medizinische Klinik

Volumn 101, Issue 3, 2006, Pages 191-197

  Sawicki, Peter T ^a   Bender, Ralf ^a   Selke, Gisbert W ^b   Klauber, Jürgen ^b   Gutschmidt, Sven ^b  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^b Wissenschaftliches Institut der AOK WIdO   (Germany)

Author keywords

Cardio and cerebrovascular events; Cox model; COX 2 inhibitors

Indexed keywords

MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DOSE RESPONSE; GASTROINTESTINAL TRACT; GERMANY; HEART INFARCTION; HUMAN; LONG TERM CARE; PRESCRIPTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CEREBRAL INFARCTION; CLINICAL TRIALS; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG AND NARCOTIC CONTROL; FEMALE; GERMANY; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; SULFONES;

EID: 33646544016     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-006-1044-6     Document Type: Article

References (18)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;284:1247-55.
2. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of selective inhibition of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
3. Mukherjee D, Nissen SE, Topol FJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-59.
4. Topol FJ. Failing the public health - rofecoxib, Merck and the FDA. N Engl J Med 2004;351:1707-9.
5. Jüni P, Nartey I, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
6. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflamatory drugs: nested case-control study. Lancet 2005;365:475-81.
7. Targum SL. Review of cardiovascular safety database for VIOXX, 01.02.2001 (http:/www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf).
8. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2-inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
9. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64.
10. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular effects associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
11. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cycooxygenase-2-inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92.
12. Aadland E, Fausa O, Vatn M, et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med 1987;83:37-40.s
13. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. The Cochrane Database Syst Rev 2002;4:CD002296.
14. Mamdani M, Juurlink DN, Kopp A, et al. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004;328:1415-6.
15. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331: 13106.
16. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366-72.
17. Lèvesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9.
18. Curfman G, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis", N Engl J Med 2000;343:152-8. N Engl J Med 2005;353:2813-4.